We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
FDA Commissioner Andrew von Eschenbach defended the agency’s budget proposal for 2008 to Congress, saying funding increases and new user fees would help accelerate drug approvals and improve product safety reviews.
Government healthcare programs must require more price transparency and better reporting to stop pharmaceutical companies from overcharging them for medications, according to experts and activists testifying at a House committee hearing.
Members of the House Committee on Energy and Commerce requested more information from the FDA regarding its approval of the antibiotic Ketek following a subcommittee hearing on the agency’s drug approval process.
Members of the House Committee on Energy and Commerce requested more information from the FDA regarding its approval of the antibiotic Ketek following a subcommittee hearing on the agency’s drug approval process.
The reintroduced “Access to Life-Saving Medicine Act,” a bill that would establish a clear and effective pathway for the FDA to approve generic copies of biologic drugs, may be attached to the Prescription Drug User Fee Act (PDUFA), congressional lawmakers said.
Members of the Senate Judiciary Committee unanimously approved Sen. Herb Kohl’s (D-Wis.) reverse-payment legislation — bringing the prohibition of that practice a step closer to becoming law.
Days before the start of a hearing challenging India’s drug patent laws, House Oversight and Government Reform Committee Chairman Henry Waxman (D-Calif.) called for an end to the challenge by Novartis, saying that a victory for the company could limit access to low-cost generic drugs.
The reintroduced “Access to Life-Saving Medicine Act,” a bill that would establish a clear and effective pathway for the FDA to approve generic copies of biologic drugs, may be attached to the Prescription Drug User Fee Act (PDUFA), congressional lawmakers said.
Members of the Senate Judiciary Committee unanimously approved Sen. Herb Kohl’s (D-Wis.) reverse-payment legislation — bringing the prohibition of that practice a step closer to becoming law.
Government healthcare programs must require more price transparency and better reporting to stop pharmaceutical companies from overcharging them for medications, according to experts and activists testifying at a recent House committee hearing.